Mimetogen Pharmaceuticals Announces Expiration of Exclusive Option Agreement with Bausch + Lomb

Source: Mimetogen Pharmaceuticals
Mimetogen Pharmaceuticals announced that effective August 31, 2014, the exclusive option agreement to license an investigational compound in development for the treatment of dry eye syndrome with Bausch + Lomb, has terminated, according to a company news release.

Mimetogen Pharmaceuticals is a private company focused on developing the use of peptidomimetics as a novel approach to treating ophthalmic diseases with high unmet medical needs. The underlying technology was developed at McGill University and the Lady Davis Institute for Medical Research in Montreal. The company is currently developing novel therapeutic approaches for indications including dry eye disease, glaucoma and other degenerative diseases of the retina.

Related Content